Ghent University Academic Bibliography

Advanced

Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma

Babett Bartling, Valerie Vanhooren UGent, Sylviane Dewaele UGent, Claude Libert UGent, Hans-Stefan Hofmann, Johannes Haerting, Sebastian Nuding, Rolf-Edgar Silber, Andreas Simm and Cuiying Chen UGent (2012) CANCER BIOMARKERS. 10(3-4). p.145-154
abstract
Successful therapy of the non-small cell lung carcinoma (NSCLC) depends on its early detection, and non-invasive detection methods are preferred. As plasma proteins are modified by N-linked glycosylation, we tested the importance of the N-glycan profile in diagnosing and prognosticating NSCLC. We analysed desialylated plasma samples from 75 NSCLC patients, and 71 healthy individuals by the high-throughput DNA sequencer-based carbohydrate analytical profiling technique. We detected alterations in the levels of several N-glycans in NSCLC patients. Total alpha-1,6-core fucosylated biantennaries (NGA2F, NG1A2F, NA2F) and total bisecting alpha-1,6-core fucosylated biantennaries (NGA2FB, NA2FB) were reduced in NSCLC patients, whereas the branching alpha-1,3-fucosylated triantennary N-glycan (NA3FB) was increased. Best diagnostic accuracy was identified for NG1A2F. NSCLC patients with TNM stage I stage did not show further differences, but patients with higher stages did (TNM II to IV). Those patients additionally had a reduced level in the alpha-1,6-core fucosylated structure NA2F with parallel increase in the non-fucosylated structure NA2. In this regard, NSCLC patients with a relatively low amount of NA2 per NA2F had a better three-year survival than patients with high amount. NSCLC patients show an altered N-glycan profile of plasma proteins that may be regarded as a supportive tool for cancer diagnosis.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
plasma, diagnosis, non-small cell lung carcinoma, N-glycan, Glycomics, CANCER, GLYCOME, DIAGNOSIS, GLYCOSYLATION, PROGNOSIS, OLIGOSACCHARIDE, IDENTIFICATION, FUCOSYLATION, ASSOCIATION, HAPTOGLOBIN
journal title
CANCER BIOMARKERS
Cancer Biomark.
volume
10
issue
3-4
pages
145 - 154
Web of Science type
Article
Web of Science id
000305157500004
JCR category
ONCOLOGY
JCR impact factor
0.972 (2012)
JCR rank
174/196 (2012)
JCR quartile
4 (2012)
ISSN
1574-0153
DOI
10.3233/CBM-2012-0239
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2971878
handle
http://hdl.handle.net/1854/LU-2971878
date created
2012-08-14 15:08:40
date last changed
2012-09-04 10:53:59
@article{2971878,
  abstract     = {Successful therapy of the non-small cell lung carcinoma (NSCLC) depends on its early detection, and non-invasive detection methods are preferred. As plasma proteins are modified by N-linked glycosylation, we tested the importance of the N-glycan profile in diagnosing and prognosticating NSCLC. We analysed desialylated plasma samples from 75 NSCLC patients, and 71 healthy individuals by the high-throughput DNA sequencer-based carbohydrate analytical profiling technique. We detected alterations in the levels of several N-glycans in NSCLC patients. Total alpha-1,6-core fucosylated biantennaries (NGA2F, NG1A2F, NA2F) and total bisecting alpha-1,6-core fucosylated biantennaries (NGA2FB, NA2FB) were reduced in NSCLC patients, whereas the branching alpha-1,3-fucosylated triantennary N-glycan (NA3FB) was increased. Best diagnostic accuracy was identified for NG1A2F. NSCLC patients with TNM stage I stage did not show further differences, but patients with higher stages did (TNM II to IV). Those patients additionally had a reduced level in the alpha-1,6-core fucosylated structure NA2F with parallel increase in the non-fucosylated structure NA2. In this regard, NSCLC patients with a relatively low amount of NA2 per NA2F had a better three-year survival than patients with high amount. NSCLC patients show an altered N-glycan profile of plasma proteins that may be regarded as a supportive tool for cancer diagnosis.},
  author       = {Bartling, Babett and Vanhooren, Valerie and Dewaele, Sylviane and Libert, Claude and Hofmann, Hans-Stefan and Haerting, Johannes and Nuding, Sebastian and Silber, Rolf-Edgar and Simm, Andreas and Chen, Cuiying},
  issn         = {1574-0153},
  journal      = {CANCER BIOMARKERS},
  keyword      = {plasma,diagnosis,non-small cell lung carcinoma,N-glycan,Glycomics,CANCER,GLYCOME,DIAGNOSIS,GLYCOSYLATION,PROGNOSIS,OLIGOSACCHARIDE,IDENTIFICATION,FUCOSYLATION,ASSOCIATION,HAPTOGLOBIN},
  language     = {eng},
  number       = {3-4},
  pages        = {145--154},
  title        = {Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma},
  url          = {http://dx.doi.org/10.3233/CBM-2012-0239},
  volume       = {10},
  year         = {2012},
}

Chicago
Bartling, Babett, Valerie Vanhooren, Sylviane Dewaele, Claude Libert, Hans-Stefan Hofmann, Johannes Haerting, Sebastian Nuding, Rolf-Edgar Silber, Andreas Simm, and Cuiying Chen. 2012. “Altered Desialylated Plasma N-glycan Profile in Patients with Non-small Cell Lung Carcinoma.” Cancer Biomarkers 10 (3-4): 145–154.
APA
Bartling, B., Vanhooren, V., Dewaele, S., Libert, C., Hofmann, H.-S., Haerting, J., Nuding, S., et al. (2012). Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma. CANCER BIOMARKERS, 10(3-4), 145–154.
Vancouver
1.
Bartling B, Vanhooren V, Dewaele S, Libert C, Hofmann H-S, Haerting J, et al. Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma. CANCER BIOMARKERS. 2012;10(3-4):145–54.
MLA
Bartling, Babett, Valerie Vanhooren, Sylviane Dewaele, et al. “Altered Desialylated Plasma N-glycan Profile in Patients with Non-small Cell Lung Carcinoma.” CANCER BIOMARKERS 10.3-4 (2012): 145–154. Print.